11 results on '"Barbaresi, William J."'
Search Results
2. Using ADHD Medications to Treat Coexisting ADHD and Reading Disorders: A Systematic Review.
- Author
-
Froehlich TE, Fogler J, Barbaresi WJ, Elsayed NA, Evans SW, and Chan E
- Subjects
- Academic Performance, Adolescent, Age Factors, Attention Deficit Disorder with Hyperactivity epidemiology, Attention Deficit Disorder with Hyperactivity physiopathology, Attention Deficit Disorder with Hyperactivity psychology, Brain physiopathology, Central Nervous System Stimulants adverse effects, Child, Comorbidity, Dyslexia epidemiology, Dyslexia physiopathology, Dyslexia psychology, Female, Humans, Male, Treatment Outcome, Adolescent Behavior drug effects, Adolescent Development drug effects, Attention Deficit Disorder with Hyperactivity drug therapy, Brain drug effects, Central Nervous System Stimulants therapeutic use, Child Behavior drug effects, Child Development drug effects, Dyslexia drug therapy
- Abstract
Attention-deficit/hyperactivity disorder (ADHD), the most common pediatric neurobehavioral disorder, frequently presents with coexisting reading disorders (RDs). Despite this, it is unclear whether medication improves symptoms and function in children with comorbid ADHD and RD. We present a systematic review of studies investigating the effects of ADHD medications on ADHD symptoms, academic outcomes, and neuropsychological measures in this important group., (© 2018 American Society for Clinical Pharmacology and Therapeutics.)
- Published
- 2018
- Full Text
- View/download PDF
3. Common Use of Stimulants and Alpha-2 Agonists to Treat Preschool Attention-Deficit Hyperactivity Disorder: A DBPNet Study.
- Author
-
Blum NJ, Shults J, Harstad E, Wiley S, Augustyn M, Meinzen-Derr JK, Wolraich ML, and Barbaresi WJ
- Subjects
- Child, Preschool, Female, Humans, Male, Practice Patterns, Physicians' statistics & numerical data, Adrenergic alpha-2 Receptor Agonists therapeutic use, Attention Deficit Disorder with Hyperactivity drug therapy, Central Nervous System Stimulants therapeutic use, Drug Prescriptions statistics & numerical data, Pediatricians statistics & numerical data
- Abstract
Objective: To describe the use of stimulants and alpha-2 agonists (A2As) for the treatment of preschool-aged children with attention-deficit hyperactivity disorder (ADHD) at 2 Developmental-Behavioral Pediatrics Research Network sites., Methods: Demographic information, diagnoses, and medications prescribed by developmental-behavioral pediatricians (DBPs) were extracted from the electronic health record for all outpatient visits from January 1, 2010, to December 31, 2011. The subset of visits for children aged 2 to 5 years who had a diagnosis of ADHD was included in this analysis. Multivariable models were constructed to identify factors associated with prescribing stimulants and A2As., Results: Over the 2-year period, 984 children with a diagnosis of ADHD were seen at 1779 visits. Of the 984 children, 342 (34.8%) were prescribed a stimulant, and 243 (24.7%) were prescribed an A2A. Both medications were prescribed at the same visit at least once during the 2-year period for 97 children (9.9%). Alpha-2 agonists were prescribed more often at site 2 than site 1 (OR [odds ratio] = 1.62, p = 0.015). Stimulants were more likely to be prescribed for older preschool-aged children (OR = 1.66, p < 0.001), and A2As were more likely to be prescribed for younger children (OR = 0.82, p = 0.02). Both stimulants and A2As were more likely to be prescribed to children with ADHD and comorbid conditions., Conclusion: Alpha-2 agonists are commonly used by some DBPs for preschool ADHD. Variation in the use of A2As across sites may indicate a lack of consensus on when to use these medications and suggests a need for comparative effectiveness research to better define the relative benefits and side effects of A2As and stimulants for the treatment of preschool ADHD.
- Published
- 2018
- Full Text
- View/download PDF
4. ADHD, stimulant treatment, and growth: a longitudinal study.
- Author
-
Harstad EB, Weaver AL, Katusic SK, Colligan RC, Kumar S, Chan E, Voigt RG, and Barbaresi WJ
- Subjects
- Adolescent, Adult, Attention Deficit Disorder with Hyperactivity physiopathology, Body Height physiology, Central Nervous System Stimulants pharmacology, Child, Child, Preschool, Cohort Studies, Female, Follow-Up Studies, Humans, Infant, Infant, Newborn, Longitudinal Studies, Male, Treatment Outcome, Young Adult, Attention Deficit Disorder with Hyperactivity drug therapy, Attention Deficit Disorder with Hyperactivity epidemiology, Body Height drug effects, Central Nervous System Stimulants therapeutic use, Population Surveillance methods
- Abstract
Background and Objective: There is ongoing concern that stimulant medications may adversely affect growth. In a sample of attention-deficit/hyperactivity disorder (ADHD) cases and controls from a population-based birth cohort, we assessed growth and the association between stimulant treatment and growth., Methods: Subjects included childhood ADHD cases (N = 340) and controls (N = 680) from a 1976 to 1982 birth cohort (N = 5718). Height and stimulant treatment information were abstracted from medical records and obtained during a prospective, adult follow-up study. For each subject, a parametric penalized spline smoothing method modeled height over time, and the corresponding height velocity was calculated as the first derivative. Peak height velocity (PHV) age and magnitude were estimated from the velocity curves. Among stimulant-treated ADHD cases, we analyzed height Z scores at the beginning, at the end, and 24 months after the end of treatment., Results: Neither ADHD itself nor treatment with stimulants was associated with differences in magnitude of PHV or final adult height. Among boys treated with stimulants, there was a positive correlation between duration of stimulant usage before PHV and age at PHV (r = 0.21, P = .01). There was no significant correlation between duration of treatment and change in height Z scores (r = -0.08 for beginning vs end change, r = 0.01 for end vs 24 months later change). Among the 59 ADHD cases treated for ≥3 years, there was a clinically insignificant decrease in mean Z score from beginning (0.48) to end (0.33) of treatment (P = .06)., Conclusions: Our findings suggest that ADHD treatment with stimulant medication is not associated with differences in adult height or significant changes in growth., (Copyright © 2014 by the American Academy of Pediatrics.)
- Published
- 2014
- Full Text
- View/download PDF
5. Update on long-term stimulant medication treatment of attention-deficit hyperactivity disorder.
- Author
-
Barbaresi WJ
- Subjects
- Adolescent, Age Factors, Attention Deficit Disorder with Hyperactivity diagnosis, Attention Deficit Disorder with Hyperactivity epidemiology, Child, Child, Preschool, Humans, Sex Factors, Time Factors, Attention Deficit Disorder with Hyperactivity drug therapy, Central Nervous System Stimulants therapeutic use, Drug Prescriptions statistics & numerical data
- Published
- 2014
- Full Text
- View/download PDF
6. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study.
- Author
-
Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Leibson CL, and Jacobsen SJ
- Subjects
- Adolescent, Attention Deficit Disorder with Hyperactivity epidemiology, Central Nervous System Stimulants administration & dosage, Central Nervous System Stimulants adverse effects, Child, Child, Preschool, Dextroamphetamine administration & dosage, Dextroamphetamine adverse effects, Female, Follow-Up Studies, Humans, Infant, Infant, Newborn, Male, Methylphenidate administration & dosage, Methylphenidate adverse effects, Minnesota epidemiology, Time Factors, Attention Deficit Disorder with Hyperactivity drug therapy, Central Nervous System Stimulants pharmacology, Dextroamphetamine pharmacology, Methylphenidate pharmacology, Treatment Outcome
- Abstract
The purpose of this study was to offer detailed information about stimulant medication treatment provided throughout childhood to 379 children with research-identified attention-deficit hyperactivity disorder (ADHD) in the 1976-1982 Rochester, MN, birth cohort. Subjects were retrospectively followed from birth until a mean of 17.2 years of age. The complete medical record of each subject was reviewed. The history and results of each episode of stimulant treatment were compared by gender, DSMIV subtype of ADHD, and type of stimulant medication. Overall, 77.8% of subjects were treated with stimulants. Boys were 1.8 times more likely than girls to be treated. The median age at initiation (9.8 years), median duration of treatment (33.8 months), and likelihood of developing at least one side effect (22.3%) were not significantly different by gender. Overall, 73.1% of episodes of stimulant treatment were associated with a favorable response. The likelihood of a favorable response was comparable for boys and girls. Treatment was initiated earlier for children with either ADHD combined type or ADHD hyperactive-impulsive type than for children with ADHD predominantly inattentive type and duration of treatment was longer for ADHD combined type. There was no association between DSM-IV subtype and likelihood of a favorable response or of side effects. Dextroamphetamine and methylphenidate were equally likely to be associated with a favorable response, but dextroamphetamine was more likely to be associated with side effects. These results demonstrate that the effectiveness of stimulant medication treatment of ADHD provided throughout childhood is comparable to the efficacy of stimulant treatment demonstrated in clinical trials.
- Published
- 2014
- Full Text
- View/download PDF
7. Stimulant medication treatment of target behaviors in children with autism: a population-based study.
- Author
-
Nickels K, Katusic SK, Colligan RC, Weaver AL, Voigt RG, and Barbaresi WJ
- Subjects
- Adolescent, Central Nervous System Stimulants administration & dosage, Central Nervous System Stimulants adverse effects, Child, Child, Preschool, Drug Utilization, Female, Humans, Male, Minnesota, Practice Patterns, Physicians', Retrospective Studies, Treatment Outcome, Autistic Disorder drug therapy, Central Nervous System Stimulants therapeutic use
- Abstract
Objective: This study provides detailed information about stimulant medication treatment for the target symptoms of hyperactivity, impulsivity, disinhibition, and inattention in children with autism., Methods: In a previous study, 124 subjects fulfilling DSM-IV-based research criteria for autistic disorder were identified among all 0-21 year old residents of Olmsted County, MN from 1976-1997. For each of these 124 children with research-identified autism, information was abstracted on all prescribed psychopharmacological medications., Results: Psychostimulants were used to treat 52.4% (N = 65) of the 124 subjects. The median total duration of psychostimulant treatment was 4.0 years. There were 398 episodes of psychostimulant treatment. Favorable responses were associated with 69.4% of treatment episodes. Of the 398 episodes of stimulant treatment, 16.8% were associated with a documented side effect. At least one side effect was experienced by 66% of the children., Conclusion: These results indicate that psychostimulants are commonly prescribed for children with autism, and suggest that these medications may improve the target symptoms of hyperactivity, impulsivity, disinhibition and inattention.
- Published
- 2008
- Full Text
- View/download PDF
8. Modifiers of long-term school outcomes for children with attention-deficit/hyperactivity disorder: does treatment with stimulant medication make a difference? Results from a population-based study.
- Author
-
Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, and Jacobsen SJ
- Subjects
- Attention Deficit Disorder with Hyperactivity epidemiology, Child, Female, Humans, Male, Population Surveillance methods, Time Factors, Achievement, Attention Deficit Disorder with Hyperactivity drug therapy, Central Nervous System Stimulants therapeutic use, Methylphenidate therapeutic use
- Abstract
Objective: The purpose of this study was to describe the significance of potential modifiers of long-term school outcomes among children with attention-deficit/hyperactivity disorder (AD/HD), including treatment with stimulant medication., Methods: Subjects included 370 children with research-identified AD/HD from a 1976-1982 population-based birth cohort (N = 5718). In a companion study, the complete school record for each subject was reviewed to obtain information on reading achievement, absenteeism, grade retention, and school dropout. Data on type of stimulant, dose, age at initiation of treatment, and start/stop dates were collected from medical and school records, available for all subjects., Results: Treatment with stimulants was associated with decreased rates of absenteeism; longer duration of treatment was also associated with decreased absenteeism rates. There was a modest positive correlation (r = .15, p = .012) between average daily stimulant dose and last reading score. Cases treated with stimulants were 1.8 times less likely to subsequently be retained a grade (95% confidence interval: 1.01-3.2; p = .047). The proportion of school dropout was similar between treated and not treated cases (22.2% vs 25.8%, p = .54). Other potential modifiers of school outcomes (sociodemographic risk factors, presence of comorbid learning or psychiatric disorders, and receipt of special educational services) were also examined and found to be associated with poorer outcomes., Conclusions: In this birth cohort, stimulant treatment of children with AD/HD was associated with improved reading achievement, decreased school absenteeism, and decreased grade retention. This study provides support for efforts to ensure that children with AD/HD receive appropriate long-term medical treatment.
- Published
- 2007
- Full Text
- View/download PDF
9. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study.
- Author
-
Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Leibson CL, and Jacobsen SJ
- Subjects
- Adolescent, Attention Deficit Disorder with Hyperactivity diagnosis, Central Nervous System Stimulants adverse effects, Child, Child, Preschool, Cohort Studies, Dextroamphetamine adverse effects, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Infant, Infant, Newborn, Likelihood Functions, Long-Term Care, Male, Methylphenidate adverse effects, Minnesota, Retrospective Studies, Sex Factors, Treatment Outcome, Attention Deficit Disorder with Hyperactivity drug therapy, Central Nervous System Stimulants administration & dosage, Dextroamphetamine administration & dosage, Methylphenidate administration & dosage
- Abstract
The purpose of this study was to offer detailed information about stimulant medication treatment provided throughout childhood to 379 children with research-identified attention-deficit hyperactivity disorder (ADHD) in the 1976-1982 Rochester, MN, birth cohort. Subjects were retrospectively followed from birth until a mean of 17.2 years of age. The complete medical record of each subject was reviewed. The history and results of each episode of stimulant treatment were compared by gender, DSM-IV subtype of ADHD, and type of stimulant medication. Overall, 77.8% of subjects were treated with stimulants. Boys were 1.8 times more likely than girls to be treated. The median age at initiation (9.8 years), median duration of treatment (33.8 months), and likelihood of developing at least one side effect (22.3%) were not significantly different by gender. Overall, 73.1% of episodes of stimulant treatment were associated with a favorable response. The likelihood of a favorable response was comparable for boys and girls. Treatment was initiated earlier for children with either ADHD combined type or ADHD hyperactive-impulsive type than for children with ADHD predominantly inattentive type and duration of treatment was longer for ADHD combined type. There was no association between DSM-IV subtype and likelihood of a favorable response or of side effects. Dextroamphetamine and methylphenidate were equally likely to be associated with a favorable response, but dextroamphetamine was more likely to be associated with side effects. These results demonstrate that the effectiveness of stimulant medication treatment of ADHD provided throughout childhood is comparable to the efficacy of stimulant treatment demonstrated in clinical trials.
- Published
- 2006
- Full Text
- View/download PDF
10. Emergency department use and costs for youth with attention-deficit/hyperactivity disorder: associations with stimulant treatment.
- Author
-
Leibson CL, Barbaresi WJ, Ransom J, Colligan RC, Kemner J, Weaver AL, and Katusic SK
- Subjects
- Adolescent, Attention Deficit Disorder with Hyperactivity economics, Central Nervous System Stimulants economics, Child, Child, Preschool, Cohort Studies, Emergency Service, Hospital economics, Humans, Retrospective Studies, Attention Deficit Disorder with Hyperactivity drug therapy, Central Nervous System Stimulants therapeutic use, Emergency Service, Hospital statistics & numerical data, Health Care Costs
- Abstract
Objective: To investigate whether, among youth with attention-deficit/hyperactivity disorder (ADHD), stimulant treatment is associated with reduced emergency department (ED) use and medical costs., Methods: We previously reviewed the complete and detailed school and medical records of all individuals born 1976-1982 in Rochester, Minn, to identify those who met criteria for ADHD between age 5 years and emigration from the area. Stimulant treatment (all start/stop dates, dosages) was also abstracted. This study followed birth cohort members with ADHD in provider-linked billing data from January 1, 1987 (billing data first available), to age 18 for outcomes: ED visits, ED costs, and medical costs. For each outcome, we analyzed associations with 1) any stimulants (yes/no), 2) proportion of follow-up time on stimulants, and 3) among those treated with stimulants, periods on versus off stimulants., Results: Of 313 youth with ADHD, 231 (74%) received any stimulants; treatment duration ranged from 14 days to 11.8 years. Treated and untreated youth were similar with respect to median annual ED visits (0.5 vs 0.5) and medical costs (661 US dollars vs 741 US dollars) (P > .05); however, increasing proportion of follow-up on stimulants was associated with fewer ED visits (P= .02) and higher medical costs (P< .001). The 231 treated youth experienced an average of 3.7 periods on and off stimulants; while receiving stimulants, they exhibited fewer ED visits (P= .02), lower ED costs (P = .03), and higher medical costs (P< .001) compared with periods off stimulants., Conclusions: Among youth with ADHD, extended stimulant treatment is associated with decreased ED visits and ED costs, but higher total medical costs.
- Published
- 2006
- Full Text
- View/download PDF
11. Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study.
- Author
-
Katusic SK, Barbaresi WJ, Colligan RC, Weaver AL, Leibson CL, and Jacobsen SJ
- Subjects
- Adolescent, Cohort Studies, Female, Humans, Male, Risk Factors, Substance-Related Disorders etiology, Attention Deficit Disorder with Hyperactivity drug therapy, Central Nervous System Stimulants therapeutic use, Substance-Related Disorders prevention & control
- Abstract
Objective: The aim of this study was to evaluate the association between stimulant treatment and the risk for substance abuse among young adults with a childhood diagnosis of attention- deficit/hyperactivity disorder (ADHD)., Methods: Subjects included 295 research-identified ADHD incidence cases treated with psychostimulant medication and 84 ADHD cases not treated with psychostimulants. These subjects are from a 1976-1982 population-based birth cohort, retrospectively, followed from birth until emigration, death, or last follow-up (mean = 17.2 years of follow-up). Medical and school records were reviewed for documented substance abuse and psychostimulant treatment. The association was evaluated using logistic regression models., Results: Socioeconomic characteristics at birth, and comorbidities, were similar between treated and untreated ADHD cases. Sixty (20.3%) of treated ADHD cases had documented substance abuse compared to 23 (27.4%) of cases not treated (OR = 0.7; 95% CI = 0.4-1.2). Among treated ADHD boys, 21.8% had substance abuse compared to 36.4% not-treated ADHD boys (OR = 0.5; 95% CI = 0.3-0.9). Among treated ADHD girls, 15.2% had substance abuse compared to 10.3% not-treated ADHD girls (OR = 1.5; 95% CI = 0.4-6.1)., Conclusion: While these results cannot demonstrate cause and effect, our findings indicate that psychostimulant treatment of childhood ADHD is associated with reduced risk for later substance abuse among boys with ADHD.
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.